WALTHAM, Mass. — Revvity Inc. said it has entered into a collaboration with Eli Lilly and Company aimed at expanding access to advanced artificial intelligence drug discovery tools by making Lilly’s TuneLab predictive models available through the Revvity Signals platform.
The collaboration builds on Revvity’s recently launched Signals Xynthetica offering and is designed to create a scalable, federated framework that allows biopharmaceutical companies to accelerate AI-enabled drug discovery while keeping proprietary data secure.
Lilly TuneLab was developed to provide the broader biotech community with access to AI and machine-learning models trained on decades of Lilly research data. In exchange, participating organizations contribute their own experimental data, which is used to improve model performance through federated learning. Under the new collaboration, the TuneLab models will be delivered directly within the Signals Xynthetica environment, where discovery teams already capture, curate, and analyze experimental data.
“Federated learning represents one of the most powerful paths forward for AI in drug discovery, but it requires the right platform to succeed,” said Kevin Willoe, president of Revvity Signals Software. “By providing access to Lilly’s worldclass predictive models through the Signals Xynthetica platform, we are creating a practical, secure way for organizations of all sizes to contribute to, and benefit from, collective intelligence.”
Through Revvity’s models-as-a-service framework, participating biotechs will be able to apply Lilly’s predictive models to their own discovery programs without exposing proprietary data. The company said this approach is particularly valuable for small and midsized biotechs, whose diverse experimental datasets can significantly enhance overall predictive performance when incorporated into federated learning networks.
Revvity said its Signals platform provides the underlying infrastructure required to support the initiative, including scientific data management, analytics, and collaboration across internal teams and external partners. The platform’s Signals One offering supports wet-lab data capture and experiment orchestration, while Signals Synergy enables secure data exchange with contract research organizations, academic collaborators, and other partners.
As part of the agreement, Revvity and Lilly will jointly fund access for selected participants, including access to Signals One and Signals Xynthetica software offerings and associated modeling credits. The companies said the co-funded model is intended to lower barriers to AI adoption and help accelerate innovation across the biotech ecosystem.
